STOCKHOLM, Sweden, July 1, 2026
AlzeCure Pharma AB has announced a landmark global out-licensing and collaboration agreement with Danish biotechnology company QuantumCell ApS for the worldwide rights to its NeuroRestore® platform, including the lead clinical-stage candidate ACD856. The agreement represents a major strategic milestone for both companies and underscores the growing commercial interest in innovative small-molecule therapies for central nervous system (CNS) diseases. Under the terms of the agreement, AlzeCure will receive an upfront payment of USD 12 million, including a USD 5 million strategic equity investment in the company at a 30% premium to its recent average share price. In addition, the collaboration includes development and commercial milestone payments, together with tiered single-digit to low double-digit royalties on future product sales. Excluding royalties, the total potential value of the agreement exceeds USD 2.2 billion, making it one of the company’s most significant licensing transactions to date and reinforcing confidence in the therapeutic potential of ACD856 for multiple neurological disorders.
NeuroRestore ACD856 Targets Multiple CNS Disorders
The centerpiece of the collaboration is ACD856, a first-in-class small-molecule positive allosteric modulator (Trk-PAM) designed to enhance NGF/TrkA and BDNF/TrkB signaling pathways, two critical neurotrophic mechanisms involved in neuronal survival, communication, and cognitive function. In preclinical studies, ACD856 has demonstrated the ability to improve learning, memory, and neuronal communication, while also exhibiting neuroprotective, anti-inflammatory, and disease-modifying properties.
The investigational therapy is currently in clinical development and is being evaluated for its potential across multiple neurological indications, including Alzheimer’s disease, Parkinson’s disease, and depression. By targeting fundamental biological mechanisms responsible for neuronal health rather than disease symptoms alone, NeuroRestore® represents a promising next-generation therapeutic platform capable of addressing several neurodegenerative and neuropsychiatric disorders where effective treatment options remain limited.
Strategic Collaboration Accelerates Global Development
Advertisement
Through the new agreement, QuantumCell ApS will assume responsibility for advancing the global development and commercialization of NeuroRestore ACD856, while leveraging its expertise as a technology-enabled biotechnology company focused on pharmaceutical innovation. The collaboration enables AlzeCure to accelerate clinical development while maintaining long-term financial participation through milestone payments and future royalties. Company leadership emphasized that the transaction validates AlzeCure’s internal research capabilities, demonstrating its ability to successfully progress innovative drug candidates from early discovery through clinical development before attracting major commercial partnerships.
The agreement is subject to customary closing conditions, including regulatory approvals under Swedish and Danish foreign direct investment regulations, before becoming fully effective. Financial advisors and legal teams from both countries supported completion of the transaction, reflecting the complexity and strategic significance of the international licensing agreement.
Licensing Deal Strengthens Alzheimer’s Drug Innovation
The collaboration further strengthens AlzeCure Pharma’s position as an innovator in small-molecule CNS therapeutics, following its broader strategy of advancing multiple proprietary research platforms targeting diseases with significant unmet medical needs. Alongside NeuroRestore®, the company continues developing additional programs including Alzstatin® and Painless, while expanding strategic collaborations within the global biopharmaceutical industry. The licensing agreement with QuantumCell highlights growing industry investment in disease-modifying therapies for neurodegenerative disorders, particularly Alzheimer’s disease, where innovative approaches capable of preserving neuronal function are urgently needed.
By combining AlzeCure’s scientific innovation with QuantumCell’s pharmaceutical development capabilities, the partnership aims to accelerate the clinical advancement of ACD856 while expanding opportunities for patients suffering from Alzheimer’s disease, Parkinson’s disease, depression, and other serious neurological disorders. The agreement also reinforces the increasing value of strategic licensing partnerships in driving innovation and commercialization across the global biopharmaceutical sector.
Source: AlzeCure press release
